Packaging Corporation of America vs Vertex Pharmaceuticals Incorporated — how do they compare? Packaging Corporation of America trades at $222.5 (market cap $20.33B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6× Packaging Corporation of America's market cap, and Packaging Corporation of America pays a 2.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PKG | VRTX | |
|---|---|---|
Market Cap | $20.33B | $122.33B |
Sector | Technology | Health |
52-Week High | $246.31 | $529.59 |
52-Week Low | $191.41 | $366.54 |
Enterprise Value | $24.16B | $117.07B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Packaging Corp of America (PKG) trades at $228.43, down 1.99% on the day, with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $8.99B revenue and 8.04% net margin, though recent earnings show mixed performance with Q1 2026 beating estimates but Q3/Q4 2025 missing. A 20% dividend increase to $6.00 annually reflects management confidence. Analyst consensus is mixed with 34.62% buy ratings and a $256.14 price target suggesting 12% upside potential.
PKG presents a balanced investment case with attractive dividend yield and analyst upside, but faces earnings volatility and margin pressure. The upcoming Q2 2026 earnings report on July 22 will be crucial for confirming growth trajectory. Key risks include integration challenges from the Greif acquisition and ongoing cost pressures affecting profitability.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Trailing returns across standard periods
Latest headlines on both assets
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →